View ValuationShin Nippon Biomedical Laboratories 향후 성장Future 기준 점검 0/6Shin Nippon Biomedical Laboratories (는) 각각 연간 0.01% 및 10.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 0.3% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.3% 로 예상됩니다.핵심 정보0.01%이익 성장률-0.33%EPS 성장률Life Sciences 이익 성장17.0%매출 성장률10.2%향후 자기자본이익률9.30%애널리스트 커버리지Low마지막 업데이트29 May 2026최근 향후 성장 업데이트공시 • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.모든 업데이트 보기Recent updates공시 • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.공시 • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026공시 • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.공시 • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026공시 • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025공시 • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025공시 • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.공시 • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.공시 • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025공시 • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025공시 • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.공시 • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024공시 • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024공시 • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.공시 • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024공시 • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.공시 • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024공시 • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.공시 • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023공시 • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.공시 • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.이익 및 매출 성장 예측OTCPK:SBLO.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202945,0444,501-477,30223/31/202840,9604,008-2,4846,32323/31/202738,3713,950-4,3346,23723/31/202632,5254,5672,9918,327N/A12/31/202531,3743,990N/AN/AN/A9/30/202534,6714,6542,0888,623N/A6/30/202533,3425,063N/AN/AN/A3/31/202532,4134,924-3,8977,035N/A12/31/202430,7014,942N/AN/AN/A9/30/202427,0743,896-11,7241,650N/A6/30/202426,1954,280N/AN/AN/A3/31/202426,4505,531-6,4982,106N/A12/31/202326,7035,503N/AN/AN/A9/30/202326,6264,607-4,0741,899N/A6/30/202326,8485,489N/AN/AN/A3/31/202325,0906,060-9504,004N/A12/31/202221,1736,231N/AN/AN/A9/30/202220,1358,0434,3827,170N/A6/30/202218,7537,245N/AN/AN/A3/31/202217,7487,1274,3395,952N/A12/31/202117,6367,432N/AN/AN/A9/30/202116,0686,0254,0755,301N/A6/30/202114,9784,844N/AN/AN/A3/31/202115,1103,6613,6294,746N/A12/31/202014,9102,421N/AN/AN/A9/30/202015,1752,8121,3892,706N/A6/30/202015,0043,234N/AN/AN/A3/31/202014,5612,5501,7883,018N/A12/31/201913,4971,990N/AN/AN/A9/30/201913,1671,915N/A2,988N/A6/30/201914,6761,524N/AN/AN/A3/31/201915,6581,950N/A2,892N/A12/31/201817,337-49N/AN/AN/A9/30/201817,928-993N/A2,943N/A6/30/201816,937-2,566N/AN/AN/A3/31/201816,600-3,555N/A1,344N/A12/31/201717,186-1,072N/AN/AN/A9/30/201717,714327N/A280N/A6/30/201717,230260N/AN/AN/A3/31/201717,244-915N/A-849N/A12/31/201615,880-1,821N/AN/AN/A9/30/201615,269-1,273N/A-3,109N/A6/30/201614,922-1,475N/AN/AN/A3/31/201614,7502,646N/A-3,339N/A12/31/201515,6372,060N/AN/AN/A9/30/201516,344401N/A-2,379N/A6/30/201517,1641,546N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SBLO.F 의 연간 예상 수익 증가율(0.01%)이 saving rate(3.5%) 미만입니다.수익 vs 시장: SBLO.F 의 연간 수익(0.01%)이 US 시장(18.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: SBLO.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SBLO.F 의 수익(연간 10.2%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SBLO.F 의 수익(연간 10.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SBLO.F의 자본 수익률은 3년 후 9.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 05:08종가2026/06/09 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Shin Nippon Biomedical Laboratories, Ltd.는 6명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yuki TsukamotoBofA Global ResearchAkitada IwasaDaiwa Securities Co. Ltd.Stephen BarkerJefferies LLC3명의 분석가 더 보기
공시 • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
공시 • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.
공시 • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026
공시 • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.
공시 • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
공시 • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
공시 • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025
공시 • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.
공시 • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.
공시 • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025
공시 • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025
공시 • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.
공시 • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024
공시 • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
공시 • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.
공시 • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024
공시 • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
공시 • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024
공시 • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.
공시 • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
공시 • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.
공시 • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.